- Home
- NAKA vs ABOS Comparison
NAKA vs ABOS Comparison
Compare NAKA & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAKA | ABOS |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.1M | 147.5M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NAKA | ABOS |
|---|---|---|
| Price | $9.39 | $2.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $13.33 | $7.60 |
| AVG Volume (30 Days) | 202.6K | ★ 491.4K |
| Earning Date | 11-18-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3,833.87 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $1.50 |
| 52 Week High | $10.53 | $3.60 |
Technical Indicators
Market Signals| Indicator | NAKA | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 57.87 | 33.44 |
| Support Level | $0.22 | $1.67 |
| Resistance Level | $10.27 | $2.77 |
| Average True Range (ATR) | 0.66 | 0.17 |
| MACD | -0.10 | -0.05 |
| Stochastic Oscillator | 54.25 | 10.53 |
Price Performance
Historical ComparisonAbout NAKA Kindly MD Inc.
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets. The firm has two principal business segments: Bitcoin Operations, which houses its Bitcoin treasury and is utilized to support investments in other Bitcoin-related companies; Healthcare Operations, which provides a patient-focused healthcare experience that provides patients personalized solutions in order to reduce opioid use and improve health outcomes. The company generates the majority of its revenue from the Healthcare Operations.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.